1). Petersen SL., Madsen HO., Ryder LP, et al. Haematopoietic stem cell transplantation with non-myeloablative conditioning in the outpatient setting: results, complications and admission requirements in a single institution. Br J Haematol. 2004. 125:225–31.
Article
2). Cao TM., Shizuru JA., Wong RM, et al. Engraftment and survival following reduced-intensity allogeneic peripheral blood hematopoietic cell transplantation is affected by CD8+ T-cell dose. Blood. 2005. 105:2300–6.
Article
3). Mielcarek M., Storb R. Graft-vs-host disease after non-myeloablative hematopoietic cell transplantation. Leuk Lymphoma. 2005. 46:1251–60.
Article
4). Ruiz-Arguelles GJ., Gomez-Almaguer D., David-Gomez-Rangel J, et al. Allogeneic hematopoietic stem cell transplantation with non-myeloablative conditioning in patients with acute myelogenous leukemia eligible for conventional allografting: a prospective study. Leuk Lymphoma. 2004. 45:1191–5.
5). Arya M., Gommersall LM., Shergill IS., Patel HR., Chao D. Non-myeloablative allogeneic stem cell transplantation: a promising new therapy in the management of metastatic renal cell cancer. BJU Int. 2005. 96:474–5.
Article
6). Rzepecki P., Zolnierek J., Sarosiek T., Langiewicz P., Szczylik C. Allogeneic non-myeloablative hematopoietic stem cell transplantation for treatment of metastatic renal cell carcinoma-single center experience. Neoplasma. 2005. 52:238–42.
7). Bornhauser M., Thiede C. Chimerism analysis after allogeneic stem cell transplantation. Haematologica. 2005. 90:1301A.
8). Seidel MG., Fritsch G., Matthes-Martin S, et al. In vitro and in vivo T-cell depletion with myeloablative or reduced-intensity conditioning in pediatric hematopoietic stem cell transplantation. Haematologica. 2005. 90:1405–14.
9). Van Deerlin VM., Leonard DG. Bone marrow engraftment analysis after allogeneic bone marrow transplantation. Clin Lab Med. 2000. 20:197–225.
Article
10). Nuckols JD., Rasheed BK., McGlennen RC., Bigner SH., Stenzel TT. Evaluation of an automated technique for assessment of marrow engraftment after allogeneic bone marrow transplantation using a commercially available kit. Am J Clin Pathol. 2000. 113:135–40.
Article
11). Thiede C., Bornhauser M., Ehninger G. Evaluation of STR informativity for chimerism testing - comparative analysis of 27 STR systems in 203 matched related donor recipient pairs. Leukemia. 2004. 18:248–54.
Article
12). Fredriksson M., Barbany G., Liljedahl U., Hermanson M., Kataja M., Syvanen AC. Assessing hematopoietic chimerism after allogeneic stem cell transplantation by multiplexed SNP genotyping using microarrays and quantitative analysis of SNP alleles. Leukemia. 2004. 18:255–66.
Article
13). Huh HJ., Huh JW., Suk Eun, et al. Clinical significance of mixed chimerism after hematopoietic stem cell transplantation. Korean J Lab Med. 2002. 22:441–6.
14). Kim TY., Park SH., Kwon EH., Kim KY., Suh JS., Sohn SK. The discrimination power and effectiveness of 3 kinds of LTR primers in the VNTR-PCR for evaluation of the engraftment of allogeneic peripheral blood stem cells transplantation. Korean J Clin Pathol. 2001. 21:527–33.
15). Promega PowerPlex 16 System. Technical Manual No. D012. 2001. URL:. http://www.promega.com/tbs/tmd012/tmd012.pdf.
16). Lion T. Summary: reports on quantitative analysis of chimerism after allogeneic stem cell transplantation by PCR amplification of microsatellite markers and capillary electrophoresis with fluorescence detection. Leukemia. 2003. 17:252–4.
Article
17). Wasch R., Bertz H., Kunzmann R., Finke J. Incidence of mixed chimaerism and clinical outcome in 101 patients after myeloablative conditioning regimens and allogeneic stem cell transplantation. Br J Hae-matol. 2000. 109:743–50.
18). Roman J., Serrano J., Jimenez A, et al. Myeloid mixed chimerism is associated with relapse in bcr-abl positive patients after unmanipulated allogeneic bone marrow transplantation for chronic myelogenous leukemia. Haematologica. 2000. 85:173–80.
19). Bader P., Beck J., Frey A, et al. Serial and quantitative analysis of mixed hematopoietic chimerism by PCR in patients with acute leukemias allows the prediction of relapse after allogeneic BMT. Bone Marrow Transplant. 1998. 21:487–95.
Article
20). de Weger RA., Tilanus MG., Scheidel KC., van den Tweel JG., Verdonck LF. Monitoring of residual disease and guided donor leukocyte infusion after allogeneic bone marrow transplantation by chimaerism analysis with short tandem repeats. Br J Hae-matol. 2000. 110:647–53.
21). Choi SJ., Lee KH., Lee JH, et al. Prognostic value of hematopoietic chimerism in patients with acute leukemia after allogeneic bone marrow transplantation: a prospective study. Bone Marrow Transplant. 2000. 26:327–32.
Article
22). Bertheas MF., Lafage M., Levy P, et al. Influence of mixed chimerism on the results of allogeneic bone marrow transplantation for leukemia. Blood. 1991. 78:3103–6.
Article
23). Najfeld V., Burnett W., Vlachos A., Scigliano E., Isola L., Fruchtman S. Interphase FISH analysis of sex-mismatched BMT utilizing dual color XY probes. Bone Marrow Transplant. 1997. 19:829–34.
Article
24). Dubovsky J., Daxberger H., Fritsch G, et al. Kinetics of chimerism during the early post-transplant period in pediatric patients with malignant and non-malignant hematologic disorders: implications for timely detection of engraftment, graft failure and rejection. Leukemia. 1999. 13:2059–69.
Article
25). McCarthy NJ., Bishop MR. Nonmyeloablative allogeneic stem cell transplantation. Oncologist. 2000. 5:487–96.